Start Date
October 7, 2024
Primary Completion Date
December 30, 2025
Study Completion Date
September 12, 2026
CD4BS CH505M5 Pr-NP1
A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered intramuscularly (IM).
CH505TF chTrimer
A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF gp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.
3M-052-AF (labeled as AP 60-702)
An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
Aluminum Hydroxide Suspension (Alum)
Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
ACU-026-001-1 (labeled as empty LNP)
An AF consisting of 4 lipid components.
Klerksdorp CRS (Site ID: 30325), Klerksdorp
Isipingo CRS (Site ID: 31635), Isipingo
The Ponce de Leon Center CRS (Site ID: 5802), Atlanta
Alabama CRS (Site ID: 31788), Birmingham
Vanderbilt Vaccine (VV) CRS (Site ID: 30352), Nashville
Setshaba Research Centre CRS (Site ID: 31829), Soshanguve
Collaborators (1)
National Institutes of Health (NIH)
NIH
Department of Health and Human Services
FED
Duke University
OTHER
Access to Advanced Health Institute (AAHI)
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH